Incyte analyst coverage
WebMar 28, 2024 · According to 13 analyst offering 12-month price targets in the last 3 months, Incyte has an average price target of $94.23 with a high of $113.00 and a low of $60.00.
Incyte analyst coverage
Did you know?
Web2 days ago · Incyte has an analyst consensus of Moderate Buy, with a price target consensus of $87.46, which is a 17.7% upside from current levels. In a report issued on April 10, RBC Capital also downgraded ... Web2 days ago · Analysts Have Conflicting Sentiments on These Healthcare Companies: Incyte (INCY) and COMPASS Pathways (CMPS) Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Incyte (INCY – Research Report) and COMPASS Pathways …
WebMar 22, 2024 · Incyte (INCY) Morgan Stanley analyst Vikram Purohit maintained a Hold rating on Incyte yesterday and set a price target of $76.00. The company’s shares closed last Tuesday at $73.49. WebApr 4, 2024 · Incyte had a net margin of 10.03% and a return on equity of 11.45%. The company had revenue of $926.70 million during the quarter, compared to analyst estimates of $880.25 million. During the same period last year, the business earned ($0.07) EPS. Incyte's quarterly revenue was up 7.4% compared to the same quarter last year.
WebMar 25, 2024 · StockNews.com assumed coverage on Incyte in a report on Thursday, March 16th. They set a "strong-buy" rating on the stock. ... The company had revenue of $926.70 million for the quarter, compared to analyst estimates of $880.25 million. Incyte had a return on equity of 11.45% and a net margin of 10.03%. The business's revenue was up 7.4% on a … WebApr 10, 2024 · The latest price target for . Incyte (NASDAQ: INCY) was reported by RBC Capital on April 10, 2024.The analyst firm set a price target for $79.00 expecting INCY to rise to within 12 months (a ...
WebAug 30, 2024 · Get the latest Incyte Corporation (INCY) stock price, news, buy or sell recommendation, and investing advice from Wall Street professionals. ... News Profile Analyst Coverage 5 Yr.
WebApr 10, 2024 · Second Setback For Incyte's LIMBER Program - Analyst Says 'Resolution Timelines Unclear To Assess Impact' Mar. 24, 2024 at 11:28 a.m. ET on Benzinga.com Incyte (INCY) Gets CRL for Jakafi Extended ... higher business assignment exampleWebMar 22, 2024 · An Incyte cancer drug that was turned down by the FDA two years ago was granted an unexpected approval Wednesday in a different type of cancer, a regulatory decision that now pits the new product... higher business discuss questionWebNov 2, 2024 · In Q3 2024 it had sales of $38 million, more than doubling its Q2 sales. Considerable time was devoted to discussing its sales ramp during the Q3 Incyte Analyst Conference. The number of potential ... higher bury street stockportWebDec 29, 2024 · Incyte ( NASDAQ: INCY) provides the potential for very high returns, based on analysts' EPS estimates and a high P/E multiple. There are also significant downside risks if EPS growth estimates... how fast is xpresspostWebApr 13, 2024 · Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States, Europe, Japan, and internationally. About the company. INCY fundamental analysis. Snowflake Score. … how fast is yoriichi tsugikuniWebSep 7, 2024 · Incyte Corp. Watch list Create INCY Alert After Hours Last Updated: Sep 7, 2024 5:14 p.m. EDT Delayed quote $ 69.20 -2.21 -3.09% After Hours Volume: 66.33K Advanced Charting Volume: 1.38M 65 Day... higher business management revisionWebJan 24, 2024 · The FDA has set a March 23 target date under the Prescription Drug User Fee Act (PDUFA) to decide on Incyte’s new drug application (NDA) for a once-daily extended-release version of ruxolitinib... higher burwardsley pub